Selank and Semax: The Russian Nootropic Peptides
Selank and semax are two peptide drugs developed and approved in Russia for anxiety and cognitive indications, almost entirely absent from Western medicine. The Russian clinical literature is substantial; Western replication is sparse.
both molecules are on the Russian state formulary; semax was developed at Moscow State University.
both are typically administered intranasally in the published Russian literature.
both are short-acting peptides with rapid CNS penetration via the olfactory route.
blinded RCTs by Western labs are essentially absent.
Selank is a synthetic heptapeptide based on tuftsin, used in Russian clinical practice for generalised anxiety disorder. Semax is a heptapeptide ACTH(4-7) analogue used for cognitive and cerebrovascular indications. Both have meaningful Russian clinical evidence bases but limited replication outside that ecosystem. The mechanism stories — BDNF modulation, monoamine regulation, neurotrophic effects — are plausible; the cross-border evidence translation is the structural problem.
Approved in Russia, invisible in Western medicine. That gap is meaningful information, not just a translation problem.
What they are
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide modelled on tuftsin, a tetrapeptide fragment of the immunoglobulin G heavy chain. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered in Russia for generalised anxiety disorder.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the ACTH(4-10) sequence. Developed at Moscow State University, it is registered in Russia for cognitive and cerebrovascular indications and used in some clinical protocols for ischaemic stroke recovery.
Both are typically administered intranasally, exploiting the olfactory-to-CNS route to deliver short peptides past the blood-brain barrier.
Proposed mechanisms
| Layer | What the research describes |
|---|---|
| BDNF / neurotrophic | Both peptides reported to increase BDNF expression in rodent models. |
| Monoamine modulation | Selank reported to influence GABA and serotonin systems; semax influences dopamine and norepinephrine. |
| Enkephalin stabilisation | Selank inhibits enkephalin degradation, potentially extending endogenous opioid signalling. |
| Anti-inflammatory CNS | Both reported to modulate neuroinflammatory markers in animal models. |
| Delivery | Intranasal route delivers peptides via olfactory neurons, bypassing first-pass metabolism. |
The mechanism stories are coherent in pieces. The integrated clinical efficacy claims rest heavily on a single regulatory and research ecosystem.
The evidence-base gap
Russian clinical literature
Substantial body of work, mostly Russian-language, including registration trials for GAD (selank) and cognitive/stroke indications (semax).
Western replication
Limited. Few blinded RCTs by independent Western labs at the scale of the Russian registration data.
Mechanistic studies
International animal and in vitro work supports BDNF and monoamine effects; the gap is at the clinical-outcome layer.
The honest interpretation is not that selank and semax don't work — the Russian clinical experience is too substantial to dismiss. It is that the cross-border evidence translation has not happened at the scale required for Western regulatory approval or for confident extrapolation.
For research framing this matters: a peptide approved in one jurisdiction and absent in another is information, especially when the mechanism is plausible and the molecules are inexpensive.
What we know, what's still open
- Russian regulatory approval: Established for both molecules, in their respective indications.
- Mechanistic plausibility: Supported by independent animal and in vitro work.
- Western RCT replication: Sparse to absent at registration scale.
- Safety: Long Russian clinical experience; short-term safety appears favourable; long-term Western pharmacovigilance data not present.
- Comparator efficacy: Versus established Western anxiolytics or nootropics, head-to-head trials are limited.
Frequently asked
Are these approved anywhere?
In Russia, yes. Not in the EU, UK or US.
Why isn't Western medicine using them?
Cross-border regulatory replication has not happened. Multiple plausible reasons: commercial incentives, language and trial-standard barriers, geopolitical factors.
Are they safe?
Russian clinical experience is favourable; long-term Western pharmacovigilance does not exist. Honest uncertainty is the correct stance.
Can they replace SSRIs?
No claim of equivalence to first-line Western pharmacotherapy is supported by current evidence.
Where to read further
- • Kozlovskaya MM et al. Selank: anxiolytic and immunomodulatory peptide. Russian literature.
- • Ashmarin IP et al. Semax: ACTH analogue cognitive peptide. Russian literature.
- • International animal mechanism studies — see PubMed for current literature.